Composition of 5-nitrobenzoate derivatives as anti-metastatic agent that inhibits tumor cell-induced platelet aggregation
US9956191B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Inventors
Key dates
| Filing date | Mar 7, 2017 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Mar 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C235/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are 5-nitrobenzoate derivatives of Formula I,and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.